Zeria Pharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Zeria Pharmaceutical has a total shareholder equity of ¥82.2B and total debt of ¥44.4B, which brings its debt-to-equity ratio to 54%. Its total assets and total liabilities are ¥152.1B and ¥69.9B respectively. Zeria Pharmaceutical's EBIT is ¥10.6B making its interest coverage ratio -182.6. It has cash and short-term investments of ¥19.9B.
Belangrijke informatie
54.0%
Verhouding schuld/eigen vermogen
JP¥44.41b
Schuld
| Rente dekkingsratio | -182.6x |
| Contant | JP¥19.90b |
| Aandelen | JP¥82.18b |
| Totaal verplichtingen | JP¥69.94b |
| Totaal activa | JP¥152.12b |
Recente financiële gezondheidsupdates
Geen updates
Analyse van de financiële positie
Kortlopende schulden: 4559's short term assets (¥60.5B) exceed its short term liabilities (¥54.6B).
Langlopende schulden: 4559's short term assets (¥60.5B) exceed its long term liabilities (¥15.4B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 4559's net debt to equity ratio (29.8%) is considered satisfactory.
Schuld verminderen: 4559's debt to equity ratio has reduced from 65.3% to 54% over the past 5 years.
Schuldendekking: 4559's debt is well covered by operating cash flow (27.4%).
Rentedekking: 4559 earns more interest than it pays, so coverage of interest payments is not a concern.